Moderna's new Covid vaccine targets omicron, improves storage

Summary: Moderna's new Covid vaccine version showed a stronger immune response in a late-stage trial, targeting omicron subvariants and the original virus. The shot aims for longer shelf life and easier storage, crucial for global distribution. The phase three trial included 11,400 participants aged 12 and older. Moderna plans to combine the new shot with a flu vaccine. Older individuals benefited the most from the enhanced immune response.

Full article